Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?

Journal of Medicinal Chemistry

Volumn 61, Issue 2, 2018, Pages 444-452

  Churcher, Ian ^a  

^a BenevolentAI   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; PEPTIDE; RECOMBINANT PROTEIN; SNAKE VENOM PROTEIN C ACTIVATOR; UBIQUITIN PROTEIN LIGASE;

ARTICLE; DRUG DEVELOPMENT; PHARMACODYNAMICS; PHARMACOLOGY; PROTEIN DEGRADATION; DRUG DESIGN; DRUG EFFECT; HUMAN; METABOLISM; MOLECULAR LIBRARY; MOLECULARLY TARGETED THERAPY; PROCEDURES; UBIQUITINATION;

DRUG DESIGN; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; PEPTIDES; PROTEOLYSIS; RECOMBINANT PROTEINS; SMALL MOLECULE LIBRARIES; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 85041108241     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.7b01272     Document Type: Article

References (69)

1. Limbird, L. E. The receptor concept: a continuing evolution Mol. Interventions 2004, 4, 326-336 10.1124/mi.4.6.6
2. Arkin, M. R.; Wells, J. A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream Nat. Rev. Drug Discovery 2004, 3, 301-317 10.1038/nrd1343
3. Sharma, V. K.; Watts, J. K. Oligonucleotide therapeutics: chemistry, delivery and clinical progress Future Med. Chem. 2015, 7, 2221-2242 10.4155/fmc.15.144
4. Barrangou, R.; Doudna, J. A. Applications of CRISPR technologies in research and beyond Nat. Biotechnol. 2016, 34, 933-941 10.1038/nbt.3659
5. Tinworth, C. P.; Lithgow, H.; Churcher, I. Small molecule-mediated protein knockdown as a new approach to drug discovery MedChemComm 2016, 7, 2206-2216 10.1039/C6MD00347H
6. Raina, K.; Crews, C. M. Targeted protein knockdown using small molecule degraders Curr. Opin. Chem. Biol. 2017, 39, 46-53 10.1016/j.cbpa.2017.05.016
7. Neklesa, T. K.; Winkler, J. D.; Crews, C. M. Targeted protein degradation by PROTACs Pharmacol. Ther. 2017, 174, 138-144 10.1016/j.pharmthera.2017.02.027
8. Lai, A. C.; Crews, C. M. Induced protein degradation: an emerging drug discovery paradigm Nat. Rev. Drug Discovery 2017, 16, 101-114 10.1038/nrd.2016.211
9. Toure, M.; Crews, C. M. Small-molecule PROTACS: new approaches to protein degradation Angew. Chem., Int. Ed. 2016, 55, 1966-1973 10.1002/anie.201507978
10. Cromm, P. M.; Crews, C. M. Targeted protein degradation: from chemical biology to drug discovery Cell Chem. Biol. 2017, 24, 1181-1190 10.1016/j.chembiol.2017.05.024
11. Nguyen, C.; West, G. M.; Geoghegan, K. F. Emerging Methods in Chemoproteomics with Relevance to Drug Discovery. In Cancer Gene Networks; Kasid, U.; Clarke, R., Eds.; Methods in Molecular Biology, Vol. 1513; Humana Press: New York, NY, 2017; DOI: 10.1007/978-1-4939-6539-7-2.
12. Juliano, R. L. The delivery of therapeutic oligonucleotides Nucleic Acids Res. 2016, 44, 6518-6548 10.1093/nar/gkw236
13. Kisselev, A. F.; van der Linden, W. A.; Overkleeft, H. S. Proteasome inhibitors: an expanding army attacking a unique target Chem. Biol. 2012, 19, 99-115 10.1016/j.chembiol.2012.01.003
14. Cohen, P.; Tcherpakov, M. Will the ubiquitin system furnish as many drug targets as protein kinases? Cell 2010, 143, 686-693 10.1016/j.cell.2010.11.016
15. Bedford, L.; Lowe, J.; Dick, L. R.; Mayer, R. J.; Brownell, J. E. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets Nat. Rev. Drug Discovery 2011, 10, 29-46 10.1038/nrd3321
16. Weissman, A. M.; Shabek, N.; Ciechanover, A. The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation Nat. Rev. Mol. Cell Biol. 2011, 12, 605-620 10.1038/nrm3173
17. Ciechanover, A. Proteolysis: from the lysosome to ubiquitin and the proteasome Nat. Rev. Mol. Cell Biol. 2005, 6, 79-87 10.1038/nrm1552
18. Hershko, A.; Ciechanover, A. The ubiquitin system for protein degradation Annu. Rev. Biochem. 1992, 61, 761-807 10.1146/annurev.bi.61.070192.003553
19. Kleiger, G.; Mayor, T. Perilous journey: a tour of the ubiquitin-proteasome system Trends Cell Biol. 2014, 24, 352-359 10.1016/j.tcb.2013.12.003
20. Komander, D. The emerging complexity of protein ubiquitination Biochem. Soc. Trans. 2009, 37, 937-953 10.1042/BST0370937
21. Douglass, E. F.; Miller, C. J.; Sparer, G.; Shapiro, H.; Spiegel, D. A. A comprehensive mathematical model for three-body binding equilibria J. Am. Chem. Soc. 2013, 135, 6092-6099 10.1021/ja311795d
22. Gadd, M. S.; Testa, A.; Lucas, X.; Chan, K. H.; Chen, W.; Lamont, D. J.; Zengerle, M.; Ciulli, A. Structural basis of PROTAC cooperative recognition for selective protein degradation Nat. Chem. Biol. 2017, 13, 514-521 10.1038/nchembio.2329
23. Petroski, M. D.; Kleiger, G.; Deshaies, R. J. Evaluation of a diffusion-driven mechanism for substrate ubiquitination by the SCF-Cdc34 ubiquitin ligase complex Mol. Cell 2006, 24, 523-534 10.1016/j.molcel.2006.10.010
24. Komander, D.; Clague, M. J.; Urbe, S. Breaking the chains: structure and function of the deubiquitinases Nat. Rev. Mol. Cell Biol. 2009, 10, 550-563 10.1038/nrm2731
25. Kravtsova-Ivantsiv, Y.; Sommer, T.; Ciechanover, A. The lysine48-based polyubiquitin chain proteasomal signal: not a single child anymore Angew. Chem., Int. Ed. 2013, 52, 192-198 10.1002/anie.201205656
26. Takahashi, K.; Matouschek, A.; Inobe, T. Regulation of proteasomal degradation by modulating proteasomal initiation regions ACS Chem. Biol. 2015, 10, 2537-2543 10.1021/acschembio.5b00554
27. Yu, H.; Kago, G.; Yellman, C. M.; Matouschek, A. Ubiquitin-like domains can target to the proteasome but proteolysis requires a disordered region EMBO J. 2016, 35, 1522-1536 10.15252/embj.201593147
28. Fishbain, S.; Prakash, S.; Herrig, A.; Elsasser, S.; Matouschek, A. Rad23 escapes degradation because it lacks a proteasome initiation region Nat. Commun. 2011, 2, 192 10.1038/ncomms1194
29. Schwanhausser, B.; Gossen, M.; Dittmar, G.; Selbach, M. Global analysis of cellular protein translation by pulsed SILAC Proteomics 2009, 9, 205-209 10.1002/pmic.200800275
30. Schwanhausser, B.; Busse, D.; Li, N.; Dittmar, G.; Schuchhardt, J.; Wolf, J.; Chen, W.; Selbach, M. Global quantification of mammalian gene expression control Nature 2011, 473, 337-342 10.1038/nature10098
31. Gosink, M. M.; Vierstra, R. D. Redirecting the specificity of ubiquitination by modifying ubiquitin-conjugating enzymes Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 9117-9121 10.1073/pnas.92.20.9117
32. Kenten, J. H.; Roberts, S. F.; Lebowitz, M. S. Controlling Protein Levels in Eukaryotic Organisms Using Novel Compounds Comprising a Ubiquitination Recognition Element and a Protein Binding Element. WO2000047220A1, 2000.
33. Sakamoto, K. M.; Kim, K. B.; Kumagai, A.; Mercurio, F.; Crews, C. M.; Deshaies, R. J. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 8554-8559 10.1073/pnas.141230798
34. Sakamoto, K. M.; Kim, K. B.; Verma, R.; Ransick, A.; Stein, B.; Crews, C. M.; Deshaies, R. J. Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation Mol. Cell. Proteomics 2003, 2, 1350-1358 10.1074/mcp.T300009-MCP200
35. Schneekloth, A. R.; Pucheault, M.; Tae, H. S.; Crews, C. M. Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics Bioorg. Med. Chem. Lett. 2008, 18, 5904-5908 10.1016/j.bmcl.2008.07.114
36. Li, H.; Hassona, M. D. H.; Lack, N. A.; Axerio-Cilies, P.; Leblanc, E.; Tavassoli, P.; Kanaan, N.; Frewin, K.; Singh, K.; Adomat, H.; Boehm, K. J.; Prinz, H.; Guns, E. T.; Rennie, P. S.; Cherkasov, A. Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancer Mol. Cancer Ther. 2013, 12, 2425-2435 10.1158/1535-7163.MCT-13-0267
37. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25 10.1016/S0169-409X(96)00423-1
38. Walters, W. P. Going further than Lipinski's rule in drug design Expert Opin. Drug Discovery 2012, 7, 99-107 10.1517/17460441.2012.648612
39. Buckley, D. L.; Gustafson, J. L.; Van Molle, I.; Roth, A. G.; Tae, H. S.; Gareiss, P. C.; Jorgensen, W. L.; Ciulli, A.; Crews, C. M. Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α Angew. Chem., Int. Ed. 2012, 51, 11463-11467 10.1002/anie.201206231
40. Buckley, D. L.; Van Molle, I.; Gareiss, P. C.; Tae, H. S.; Michel, J.; Noblin, D. J.; Jorgensen, W. L.; Ciulli, A.; Crews, C. M. Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction J. Am. Chem. Soc. 2012, 134, 4465-4468 10.1021/ja209924v
41. Buckley, D. L.; Raina, K.; Darricarrere, N.; Hines, J.; Gustafson, J. L.; Smith, I. E.; Miah, A. H.; Harling, J. D.; Crews, C. M. HaloPROTACS: Use of small molecule PROTACs to induce degradation of HaloTag fusion proteins ACS Chem. Biol. 2015, 10, 1831-1837 10.1021/acschembio.5b00442
42. Crews, C. M.; Buckley, D. L.; Ciulli, A.; Jorgensen, W.; Gareiss, P. C.; Van Molle, I.; Gustafson, J.; Tae, H.-S.; Michel, J.; Hoyer, D. W.; Roth, A. G.; Harling, J. D.; Smith, I. E. D.; Miah, A. H.; Campos, S. A.; Le, J. Compounds and Methods for the Inhibition of VCB E3 Ubiquitin Ligase. WO2013/106646A2, 2013.
43. Van Molle, I.; Thomann, A.; Buckley, D. L.; So, E. C.; Lang, S.; Crews, C. M.; Ciulli, A. Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1α protein-protein interface Chem. Biol. 2012, 19, 1300-1312 10.1016/j.chembiol.2012.08.015
44. Galdeano, C.; Gadd, M. S.; Soares, P.; Scaffidi, S.; Van Molle, I.; Birced, I.; Hewitt, S.; Dias, D. M.; Ciulli, A. Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities J. Med. Chem. 2014, 57, 8657-8663 10.1021/jm5011258
45. Bondeson, D. P.; Mares, A.; Smith, I. E.; Ko, E.; Campos, S.; Miah, A. H.; Mulholland, K. E.; Routly, N.; Buckley, D. L.; Gustafson, J. L.; Zinn, N.; Grandi, P.; Shimamura, S.; Bergamini, G.; Faelth-Savitski, M.; Bantscheff, M.; Cox, C.; Gordon, D. A.; Willard, R. R.; Flanagan, J. J.; Casillas, L. N.; Votta, B. J.; den Besten, W.; Famm, K.; Kruidenier, L.; Carter, P. S.; Harling, J. D.; Churcher, I.; Crews, C. M. Catalytic in vivo protein knockdown by small-molecule PROTACs Nat. Chem. Biol. 2015, 11, 611-617 10.1038/nchembio.1858
46. Winter, G. E.; Buckley, D. L.; Paulk, J.; Roberts, J. M.; Souza, A.; Dhe-Paganon, S.; Bradner, J. E. Phthalimide conjugation as a strategy for in vivo target protein degradation Science 2015, 348, 1376-1381 10.1126/science.aab1433
47. Lu, J.; Qian, Y.; Altieri, M.; Dong, H.; Wang, J.; Raina, K.; Hines, J.; Winkler, J. D.; Crew, A. P.; Coleman, K.; Crews, C. M. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4 Chem. Biol. 2015, 22, 755-763 10.1016/j.chembiol.2015.05.009
48. Zengerle, M.; Chan, K. H.; Ciulli, A. Selective small molecule induced degradation of the BET bromodomain Protein BRD4 ACS Chem. Biol. 2015, 10, 1770-1777 10.1021/acschembio.5b00216
49. Nulsen, R. O. Trial of thalidomide in insomnia associated with the third trimester Am. J. Obstet. Gynecol. 1961, 81, 1245-1248 10.1016/S0002-9378(15)33360-3
50. Fischer, E. S.; Bohm, K.; Lydeard, J. R.; Yang, H.; Stadler, M. B.; Cavadini, S.; Nagel, J.; Serluca, F.; Acker, V.; Lingaraju, G. M.; Tichkule, R. B.; Schebesta, M.; Forrester, W. C.; Schirle, M.; Hassiepen, U.; Ottl, J.; Hild, M.; Beckwith, R. E.; Harper, J. W.; Jenkins, J. L.; Thoma, N. H. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide Nature 2014, 512, 49-53 10.1038/nature13527
51. Chamberlain, P. P.; Lopez-Girona, A.; Miller, K.; Carmel, G.; Pagarigan, B.; Chie-Leon, B.; Rychak, E.; Corral, L. G.; Ren, Y. J.; Wang, M.; Riley, M.; Delker, S. L.; Ito, T.; Ando, H.; Mori, T.; Hirano, Y.; Handa, H.; Hakoshima, T.; Daniel, T. O.; Cathers, B. E. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs Nat. Struct. Mol. Biol. 2014, 21, 803-809 10.1038/nsmb.2874
52. Yang, N. J.; Hinner, M. J. Getting across the cell membrane: an overview for small molecules, peptides, and proteins Methods Mol. Biol. 2015, 1266, 29-53 10.1007/978-1-4939-2272-7-3
53. Kelder, J.; Grootenhuis, P. D.; Bayada, D. M.; Delbressine, L. P.; Ploemen, J. P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs Pharm. Res. 1999, 16, 1514-1519 10.1023/A:1015040217741
54. Atack, J. R. GABA-A receptor subtype-selective modulators. II. alpha5-selective inverse agonists for cognition enhancement Curr. Top. Med. Chem. 2011, 11, 1203-1214 10.2174/156802611795371314
55. Lai, A. C.; Toure, M.; Hellerschmied, D.; Salami, J.; Jaime-Figueroa, S.; Ko, E.; Hines, J.; Crews, C. M. Modular PROTAC design for the degradation of oncogenic BCR-ABL Angew. Chem., Int. Ed. 2016, 55, 807-810 10.1002/anie.201507634
56. Saenz, D. T.; Fiskus, W.; Qian, Y.; Manshouri, T.; Rajapakshe, K.; Raina, K.; Coleman, K. G.; Crew, A. P.; Shen, A.; Mill, C. P.; Sun, B.; Qiu, P.; Kadia, T. M.; Pemmaraju, N.; DiNardo, C.; Kim, M. S.; Nowak, A. J.; Coarfa, C.; Crews, C. M.; Verstovsek, S.; Bhalla, K. N. Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells Leukemia 2017, 31, 1951-1961 10.1038/leu.2016.393
57. Raina, K.; Lu, J.; Qian, Y.; Altieri, M.; Gordon, D.; Rossi, A. M.; Wang, J.; Chen, X.; Dong, H.; Siu, K.; Winkler, J. D.; Crew, A. P.; Crews, C. M.; Coleman, K. G. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer Proc. Natl. Acad. Sci. U. S. A. 2016, 113, 7124-7129 10.1073/pnas.1521738113
58. Ohoka, N.; Okuhira, K.; Ito, M.; Nagai, K.; Shibata, N.; Hattori, T.; Ujikawa, O.; Shimokawa, K.; Sano, O.; Koyama, R.; Fujita, H.; Teratani, M.; Matsumoto, H.; Imaeda, Y.; Nara, H.; Cho, N.; Naito, M. In vivo knockdown of pathogenic proteins via specific and nongenetic inhibitor of apoptosis protein (IAP)-dependent protein erasers (SNIPERs) J. Biol. Chem. 2017, 292, 4556-4570 10.1074/jbc.M116.768853
59. Remillard, D.; Buckley, D. L.; Paulk, J.; Brien, G. L.; Sonnett, M.; Seo, H. S.; Dastjerdi, S.; Wuhr, M.; Dhe-Paganon, S.; Armstrong, S. A.; Bradner, J. E. Degradation of the BAF complex factor BRD9 by heterobifunctional ligands Angew. Chem., Int. Ed. 2017, 56, 5738-5743 10.1002/anie.201611281
60. Jin, M.; Crew, A. P.; Dong, H.; Wang, J.; Siu, K.; Ferraro, C.; Chen, X.; Qian, Y. Preparation of Thioxoimidazolidinone Compounds and Methods for the Targeted Degradation of the Androgen Receptor. WO2016118666A1, 2016.
61. Jin, J.; Sklar, G. E.; Oh, V. M. S.; Li, S. C. Factors affecting therapeutic compliance: A review from the patient's perspective Ther. Clin. Risk Manage. 2008, 4, 269-286 10.2147/TCRM.S1458
62. Narayanan, R.; Miller, D. D.; Ponnusamy, T.; Hwang, D.-J.; Pagadala, J.; Duke, C. B.; Coss, C. C.; Dalton, J. T.; He, Y. Preparation of Novel Indole, Indazole, Benzimidazole, Indoline, Quinolone, Isoquinoline, and Carbazole Selective Androgen Receptor Degrader (SARD) Ligands. US20170095446A1, 2017.
63. McDonnell, D. P.; Wardell, S. E.; Norris, J. D. Oral selective estrogen receptor downregulators (SERDs), a breakthrough endocrine therapy for breast cancer J. Med. Chem. 2015, 58, 4883-4887 10.1021/acs.jmedchem.5b00760
64. Collins, G. A.; Goldberg, A. L. The logic of the 26S proteasome Cell 2017, 169, 792-806 10.1016/j.cell.2017.04.023
65. Demizu, Y.; Shibata, N.; Hattori, T.; Ohoka, N.; Motoi, H.; Misawa, T.; Shoda, T.; Naito, M.; Kurihara, M. Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand Bioorg. Med. Chem. Lett. 2016, 26, 4865-4869 10.1016/j.bmcl.2016.09.041
66. Li, W.; Bengtson, M. H.; Ulbrich, A.; Matsuda, A.; Reddy, V. A.; Orth, A.; Chanda, S. K.; Batalov, S.; Joazeiro, C. A. P. Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling PLoS One 2008, 3, e1487 10.1371/journal.pone.0001487
67. Janse, D. M.; Crosas, B.; Finley, D.; Church, G. M. Localization to the proteasome is sufficient for degradation J. Biol. Chem. 2004, 279, 21415-21420 10.1074/jbc.M402954200
68. Lebraud, H.; Wright, D. J.; Johnson, C. N.; Heightman, T. D. Protein degradation by in-cell self-assembly of proteolysis targeting chimeras ACS Cent. Sci. 2016, 2, 927-934 10.1021/acscentsci.6b00280
69. Jog, R.; Burgess, D. J. Pharmaceutical amorphous nanoparticles J. Pharm. Sci. 2017, 106, 39-65 10.1016/j.xphs.2016.09.014